One of the most significant barriers to accessing GLP-1 receptor agonist medications such as semaglutide and tirzepatide is their substantial cost. At list price, these medications represent monthly expenditures that are out of reach for most patients without meaningful insurance coverage or manufacturer assistance. Understanding the landscape of pricing, insurance coverage, and available assistance programs is essential for patients seeking sustainable access to these therapies.
Current List Prices
As of 2024–2025, the approximate U.S. list prices (without insurance) for GLP-1 RA medications are:
- Wegovy (semaglutide 2.4 mg, weekly injection for obesity): Approximately $1,349 per month
- Ozempic (semaglutide 0.5–2 mg, weekly injection for type 2 diabetes): Approximately $935–$1,000 per month depending on dose
- Zepbound (tirzepatide 2.5–15 mg, weekly injection for obesity): Approximately $1,059 per month at maintenance doses
- Mounjaro (tirzepatide for type 2 diabetes): Approximately $1,000–$1,100 per month
- Rybelsus (oral semaglutide, for type 2 diabetes): Approximately $870–$950 per month
These list prices represent the maximum potential out-of-pocket cost. The actual cost to a given patient depends heavily on insurance coverage and assistance program eligibility.
Insurance Coverage: The Complex Reality
Insurance coverage for GLP-1 RA is fragmented and has been a major policy controversy. Coverage patterns differ significantly based on the indication for which the medication is prescribed:
- Type 2 diabetes indication (Ozempic, Mounjaro, Rybelsus): Coverage is significantly more common for the diabetes indications. Most commercial insurance plans and Medicare Part D cover these medications for patients with confirmed type 2 diabetes, though tier placement and prior authorization requirements vary.
- Obesity/weight management indication (Wegovy, Zepbound): Coverage is far more inconsistent. Historically, many commercial insurers and Medicare explicitly excluded weight management medications. As of 2024, Medicare coverage of Wegovy and Zepbound remains limited but is expanding, particularly for patients with confirmed cardiovascular disease (supported by the SELECT trial cardiovascular indication).
- Medicaid: Coverage varies by state. Some states cover GLP-1 RA for obesity; others do not. Patients should check their specific state Medicaid formulary.
- Employer-sponsored insurance: An increasing number of large employers are adding GLP-1 RA coverage for obesity as evidence of cardiovascular and productivity benefits accumulates, though many smaller employers have not yet done so due to premium impact concerns.
💡 💡 Clinical Pearl: The Cardiovascular Indication — A Coverage Gateway
The SELECT trial (Lincoff AM, et al., 2023, NEJM) demonstrated that semaglutide 2.4 mg reduces major cardiovascular events by 20% in patients with pre-existing cardiovascular disease and obesity (without diabetes). Based on this data, the FDA approved an expanded indication for Wegovy for cardiovascular risk reduction. This cardiovascular indication may provide an additional pathway for insurance coverage for eligible patients — those with obesity and established CVD (prior heart attack, stroke, or peripheral arterial disease). Discuss this indication with your prescribing physician if applicable. For more on these outcomes, see Long-Term GLP-1 RA Benefits.
Manufacturer Patient Assistance and Savings Programs
Both Novo Nordisk (Wegovy, Ozempic) and Eli Lilly (Zepbound, Mounjaro) offer savings programs that can dramatically reduce out-of-pocket costs for eligible patients:
- Novo Nordisk NovoCare Program: Commercially insured patients may pay as little as $0/month for the first month and reduced rates thereafter through manufacturer coupons. Income-based uninsured assistance is also available through the NovoCare Patient Assistance Program.
- Eli Lilly LillyDirect / Zepbound Savings Card: Eligible commercially insured patients can receive savings cards reducing co-pays to approximately $25–$150/month. Lilly also offers a direct-to-patient program at substantially reduced prices for cash-pay patients.
- Ozempic Savings Card: For type 2 diabetes patients with commercial insurance, Novo Nordisk offers savings cards that can reduce co-pays to approximately $25–$99/month.
Important caveat: These manufacturer savings programs are generally only available to patients with commercial insurance or those who are uninsured. Patients with Medicare, Medicaid, or other federal insurance programs are typically not eligible for manufacturer coupon programs due to federal anti-kickback statute restrictions.
Insurance Appeal Strategies
When insurance initially denies coverage for a GLP-1 RA, patients have appeal rights. Effective strategies include:
- Prior authorization with comprehensive documentation: Ensure your physician submits detailed documentation of obesity-related comorbidities (sleep apnea, hypertension, type 2 diabetes, cardiovascular disease, joint disease), prior weight loss attempts, and clinical necessity. Many initial denials are overturned on first appeal.
- Peer-to-peer review: Ask your physician to request a peer-to-peer review with the insurance medical director. Physicians who advocate directly for their patients in these reviews have significantly higher success rates.
- Step therapy requirements: Some insurers require documented failure of other interventions before approving GLP-1 RA. Compile records of prior weight loss attempts and other medication trials.
- State insurance commissioner complaints: If appeals are exhausted, filing a complaint with the state insurance commissioner may prompt insurer reconsideration, particularly if a denial appears to violate parity laws or state coverage mandates.
Alternative Affordability Approaches
- Transparent pricing platforms: Various platforms now offer transparent prescription pricing. While Wegovy-equivalent semaglutide 2.4 mg remains brand-only, monitoring these platforms may reveal competitive pricing options.
- GoodRx and prescription discount programs: While typically showing significant discounts for generic drugs, GoodRx prices for brand GLP-1 RA are typically only modestly below list price and rarely competitive with manufacturer savings cards.
- Telehealth platforms: Platforms offering GLP-1 RA prescriptions should be verified as dispensing FDA-approved branded medications rather than compounded versions — see The Dangers of Compounded GLP-1 RA for why this distinction matters critically.
💡 Frequently Asked Questions (FAQ)
Q1: Does Medicare cover Wegovy or Zepbound for weight loss?
A1: Historically, Medicare Part D did not cover anti-obesity medications. Coverage is evolving: as of 2024, Medicare covers Wegovy for its cardiovascular risk reduction indication in patients with obesity and pre-existing cardiovascular disease. Coverage for obesity alone remains limited, but policy changes are ongoing. Check with Medicare directly or consult a benefits counselor for the most current information.
Q2: My insurance denied GLP-1 RA. Should I give up?
A2: Absolutely not. A large percentage of initial denials are overturned on appeal when comprehensive clinical documentation is provided. Work closely with your physician’s office to submit a thorough appeal with supporting medical records, and consider requesting a peer-to-peer review between your physician and the insurance medical director.
Q3: What is the cheapest legitimate way to access Wegovy or Zepbound without insurance?
A3: Eli Lilly’s LillyDirect program offers Zepbound directly to patients at significantly reduced cash prices compared to list price. Novo Nordisk’s NovoCare program offers income-based assistance for uninsured patients. Discuss these options with your physician or contact manufacturer assistance lines directly. Do not purchase compounded versions as a cost-saving measure — the safety risks are not worth it.
📚 References & Sources
- Lincoff, A.M., et al. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT trial). New England Journal of Medicine, 389(24), 2221–2232.
- Shrank, W.H., et al. (2019). Waste in the US health care system: estimated costs and potential for savings. JAMA, 322(15), 1501–1509.
- FDA. (2023). FDA approves new indication for Wegovy (semaglutide) to reduce risk of serious heart problems in adults with obesity. FDA News Release.